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Concerns about the dwindling number of physician scientists have led the NIH and Association of American Medical Colleges (AAMC) to develop initiatives to address this gap. [3] [4] [5] [6] The 2002 NIH Roadmap Initiative aimed to bridge the gap between pathophysiologic advances and clinical care. The AAMC released a report in 2006 calling for medical schools and teaching hospitals to incorporate courses in clinical and translational research into medical student and residency training. 7 Ensuring an adequate future workforce is one of the major challenges facing the national clinical research enterprise. 2 There are a variety of postresidency training options available for individuals interested in a career in clinical research in the neurologic sciences. Both programs provide both preceptorial and didactic teaching, but with slightly different emphasis. In both programs fellows participate in coursework in biostatistics, data analysis and computing, and ethics in research, which can be expanded into a formal Master's degree program (MPH, MS-CI, MSTr). The UCB program has a larger emphasis on pharmacology, with courses in pharmacokinetics, dynamics, or genetics, and molecular biology and drug metabolism. The URMC program has developed 3 seminar programs to complement formal coursework: 1) Working Group on Clinical Trials, 2) Mechanisms of Disease and Therapeutic Development Workshop, and 3) Mellow Fellows. The twicemonthly Working Group Seminars provide an interactive forum for Neurology, Biostatistics, and Community and Preventive Medicine junior and senior faculty to discuss planned or in progress clinical trials, pilot data, and ideas for future studies. This forum is complemented by Mellow Fellows, an informal research-social meeting held monthly designed to provide fellows an opportunity to brainstorm new ideas with experienced investigators, biostatisticians, and each other. The Mechanisms of Disease Workshop focuses on the molecular underpinnings and basic science advances that may lead to therapeutic interventions. Both programs are flexible and tailored to a great degree on the needs of the fellow. In both programs the first year is largely comprised of coursework and designing and implementing fellow-initiated research projects.
During the first year fellows in the UCB program participate in brief exposures to various aspects of drug development at UCB Biosciences complemented by fellow-initiated research projects at Duke, UNC, or the Hamner. The UCB Biosciences experience expands to an intensive (4 days/week), hands-on participation in all aspects of drug development during the second year. This directly builds upon core knowledge in developing, reviewing, and composing protocols and regulatory submissions, and fellows magnify understanding of the process of execution of phase I-III clinical trials, including site selection, start-up, and monitoring, as well as issues of human subjects protection and recruitment.
The heart of the URMC program is its formal one-on-one mentoring program. The preceptorial team always includes a clinical neuroscientist and biostatistician. A basic neuroscientist and other clinical neuroscientists are often involved. The trainee and mentors work together to develop a long-term plan for training that includes development of one or more hypothesis-driven clinical research projects. The team meets regularly, typically on a weekly basis, to review and discuss the progress of the project. As it is not typically feasible to conceive, develop, and execute a clinical trial from beginning to completion during the fellowship period, each trainee is invited to participate in ongoing clinical trials at various stages of execution in order to directly learn about the process of drug development. Trainee roles have included medical monitor, steering committee member, subinvestigator, and writing group member, among others. Direct experience is a critical component of the educational program. 
